Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients.
Chemotherapy holiday
Nab-paclitaxel
Pancreatic cancer
Re-challenge
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
24
06
2020
accepted:
20
10
2020
pubmed:
8
11
2020
medline:
24
6
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
We aimed to explore the role of drugs re-challenge at the disease progression after a chemotherapy-free interval for pancreatic adenocarcinoma (PDAC) patients. We retrospectively analyzed the outcome of re-treatments at the progression in two cohorts of advanced PDAC patients who had disease control (DC) and a treatment holiday ≥ 3 months after upfront chemotherapy. Between 2015 and 2019, 66 advanced PDAC patients (cohort A) had DC with nab-paclitaxel-based chemotherapy (i.e. AG or PAXG = cisplatin, nab-paclitaxel, gemcitabine, capecitabine). At the time of progressive disease (PD), 34 patients were re-treated with AG (A1) and 32 were treated with other regimens (A2). The median (m) duration of chemotherapy holiday was 6.1 and 5.9 months in A1 and A2, respectively. Partial response (PR) and stable disease (SD) were found in 14 (41%) and 12 (35%) of patients in A1 and in 8 (25%) and 6 (19%) patients in A2. CA19-9 response was recorded in 23/33 evaluable patients (70%) in A1 and in 5/20 (25%) in A2. mPFS2 and mOS2, defined as the time between the second line of treatment start and the disease progression or death, were 4.8 and 12.2 months in A1 and 3.9 and 8.4 months in A2, respectively. Similarly, between 2006 and 2013, 64 patients (cohort B) had DC with upfront PEFG/PEXG/PDXG regimens (epirubicin or docetaxel, cisplatin, gemcitabine, capecitabine or 5-fluorouracil) and were re-treated at PD with either 4-drug (B1; N = 30) or other regimens (B2; N = 34), yielding a mOS2 of 10.9 and 7.2 months, respectively. Our data endorse the strategy of resuming prior drugs after a chemotherapy holiday ≥ 3 months in advanced PDAC patients who achieved a durable disease control after upfront treatments.
Identifiants
pubmed: 33159215
doi: 10.1007/s00280-020-04190-1
pii: 10.1007/s00280-020-04190-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-101Références
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825
doi: 10.1056/NEJMoa1011923
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703
doi: 10.1056/NEJMoa1304369
Relias V, Maloney A, Smith MH, Wasif Saif M (2017) Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine? Cancer Chemother Pharmacol 80:371–375
doi: 10.1007/s00280-017-3374-x
Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D (2013) Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res 32(1):92
doi: 10.1186/1756-9966-32-92
Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, Mileset D (2010) Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol 7(10):561–574
doi: 10.1038/nrclinonc.2010.122
Colombo N, Gore M (2007) Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 64(2):129–138
doi: 10.1016/j.critrevonc.2007.04.004
Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Ardine M, Barniet S (2013) Platinum rechallenge in patients with advanced NSCLC: a pooled analysis. Lung Cancer 81(3):337–342
doi: 10.1016/j.lungcan.2013.06.022
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne P-L, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 24(3):394–400
doi: 10.1200/JCO.2005.03.0106
Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 27:5727–5733
doi: 10.1200/JCO.2009.23.4344
Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K (2010) The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 46(10):1770–1777
doi: 10.1016/j.ejca.2010.04.010
Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734–741
doi: 10.1007/s00415-009-5006-9
Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, Pliskat H, Frohn C, Hess G (2010) Bortezomib retreatment in relapsed multiple myeloma—results from a retrospective multicenter survey in Germany and Switzerland. Oncology 79:247–254
doi: 10.1159/000322866
Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS (2013) Drug rechallenge and treatment beyond progression—implication for drug resistance. Nat Rev Clin Oncol 10(10):571–587
doi: 10.1038/nrclinonc.2013.158
Reni M, Zanon S, Peretti U, Chiaravalli M, Barone D, Pircher C, Balzano G, Macchini M, Romi S, Gritti E, Mazza E, Nicoletti R, Doglioni C, Falconi M, Gianni L (2018) Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Lancet Gastroenterol Hepatol 3(10):691–697
doi: 10.1016/S2468-1253(18)30196-1
Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E (2012) A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 69:115–123
doi: 10.1007/s00280-011-1680-2
Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V (2007) Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 59(3):361–367
doi: 10.1007/s00280-006-0277-7
Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V, Villa E (2009) Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115:2630–2639
doi: 10.1002/cncr.24302
Reni M, Peretti U, Zanon S, Macchini M, Balzano G, Mazza E, Tamburrino D, Orsi G, Arcidiacono PG, Falconi M, Gianni L (2020) Time to CA19.9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 85(4):641–650
doi: 10.1007/s00280-020-04047-7
Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhattet RS (2011) High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med 9:220
doi: 10.1186/1479-5876-9-220
Solit DB, She Y, Lobo J, Kris MG, Scher HI, Rosen N, Sirotnak FM (2005) Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11:1983–1989
doi: 10.1158/1078-0432.CCR-04-1347
Rimawi MF, Wiechmann LS, Wang Y-C, Huang C, Migliaccio I, Wu M-F, Gutierrez C, Hilsenbeck SG, Arpino G, Ward SMR, Soliz R, Osborne CK, Schiff R (2011) Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in Her2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17:1351–1361
doi: 10.1158/1078-0432.CCR-10-1905
Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D’Amico M, DeCensi A, Bruzzi P (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 29:2144–2149
doi: 10.1200/JCO.2010.31.5374
Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O’Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Norton GKL, Muss H, Winer EP, Hudis C (2012) Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol 30(33):4071–4076
doi: 10.1200/JCO.2011.40.6405
Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325:1342–1348
doi: 10.1056/NEJM199111073251904